Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Recombinant Fusion Proteins"" wg kryterium: Temat


Tytuł:
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Autorzy:
Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lee J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Vikhe P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Schalk DR; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Fray E; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kumar M; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Schultz-Darken N; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Rakasz E; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Capuano S; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ladd RA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Jeng EK; Altor Biosciences, Miramar, FL 33027, USA.
Seaman M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Martin M; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Van Dorp C; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.; Santa Fe Institute, Santa Fe, NM 87501, USA.
Wong HC; Altor Biosciences, Miramar, FL 33027, USA.
Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Siliciano R; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Safrit JT; ImmunityBio, Culver City, CA 90232, USA.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soon-Shiong P; ImmunityBio, Culver City, CA 90232, USA.
Nussenzweig M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.; Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 08; Vol. 383 (6687), pp. 1104-1111. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Retroviral Agents*/therapeutic use
Anti-Retroviral Agents*/pharmacology
Simian Acquired Immunodeficiency Syndrome*/drug therapy
Simian Acquired Immunodeficiency Syndrome*/therapy
Simian Immunodeficiency Virus*
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/pharmacology
Animals ; Humans ; Broadly Neutralizing Antibodies/administration & dosage ; CD8-Positive T-Lymphocytes/virology ; Immunotherapy ; Macaca mulatta ; Viral Load ; Remission Induction ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry.
Autorzy:
Kishnani PS; Department of Pediatrics, Duke University Medical Center, 2351 Erwin Road, Durham, NC, 27710, USA. .
Martos-Moreno GÁ; Hospital Infantil Universitario Niño Jesús, IIS La Princesa, Universidad Autónoma de Madrid, CIBERobn, ISCIII, Madrid, Spain.
Linglart A; Paris-Saclay University, AP-HP and INSERM, Paris, France.
Petryk A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Messali A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Fang S; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Rockman-Greenberg C; University of Manitoba, Winnipeg, MB, Canada.
Ozono K; Osaka University, Suita, Osaka, Japan.
Högler W; Johannes Kepler University Linz, Linz, Austria.
Seefried L; University of Würzburg, Würzburg, Germany.
Dahir KM; Vanderbilt University Medical Center, Nashville, TN, USA.
Pokaż więcej
Źródło:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Mar 08; Vol. 19 (1), pp. 109. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Hypophosphatasia*/drug therapy
Chronic Pain*
Immunoglobulin G*
Recombinant Fusion Proteins*
Adult ; Humans ; Alkaline Phosphatase/therapeutic use ; Quality of Life ; Prospective Studies ; Registries ; Enzyme Replacement Therapy/methods
Czasopismo naukowe
Tytuł:
Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Autorzy:
Huang L; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Qian G; Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Zhang H; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Li Q; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Chen L; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Tang X; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Zhao H; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Feb; Vol. 33 (2), pp. 172-175. Date of Electronic Publication: 2023 Dec 11.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/drug therapy
Lupus Nephritis*/drug therapy
Recombinant Fusion Proteins*
Humans ; Female ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Immunosuppressive Agents/therapeutic use
Czasopismo naukowe
Tytuł:
Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept.
Autorzy:
Sayanagi K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan. .
Fujimoto S; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Hara C; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Fukushima Y; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Maruyama K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Kawasaki R; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Sato S; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Nishida K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 21; Vol. 14 (1), pp. 1833. Date of Electronic Publication: 2024 Jan 21.
Typ publikacji:
Journal Article
MeSH Terms:
Macula Lutea*
Polyps*/drug therapy
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Polypoidal Choroidal Vasculopathy ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
Autorzy:
Fan Q; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ji H; Department of Dermatology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu Y; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jia C; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zou L; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yang H; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Apr; Vol. 33 (4), pp. 414-419. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/complications
Lupus Erythematosus, Systemic*/drug therapy
Hepatitis*/drug therapy
Recombinant Fusion Proteins*
Antibodies, Monoclonal, Humanized*
Humans ; Prospective Studies ; Treatment Outcome ; Immunosuppressive Agents/therapeutic use
Czasopismo naukowe
Tytuł:
IL-15 and N-803 for HIV Cure Approaches.
Autorzy:
Howard JN; Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC 20037, USA.
Bosque A; Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC 20037, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Sep 12; Vol. 15 (9). Date of Electronic Publication: 2023 Sep 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
HIV Infections*/drug therapy
HIV-1*/physiology
Recombinant Fusion Proteins*
Humans ; Virus Latency ; Interleukin-15 ; CD4-Positive T-Lymphocytes ; Virus Activation
Czasopismo naukowe
Tytuł:
Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.
Autorzy:
Kaidun P; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Holzmayer SJ; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Greiner SM; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Seller A; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Tegeler CM; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Hagelstein I; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Mauermann J; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Engler T; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Koch A; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Hartkopf AD; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Märklin M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Aug 24; Vol. 24 (17). Date of Electronic Publication: 2023 Aug 24.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Recombinant Fusion Proteins*/therapeutic use
Humans ; Administration, Cutaneous ; Aggression ; Ligands ; NK Cell Lectin-Like Receptor Subfamily K/genetics ; Receptors, IgG ; CD3 Complex
Czasopismo naukowe
Tytuł:
Engineered Chimera Protein Constructs to Facilitate the Production of Heterologous Transmembrane Proteins in E. coli .
Autorzy:
Ogunbowale A; Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
Georgieva ER; Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 16; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Escherichia coli*/genetics
Escherichia coli*/metabolism
Escherichia coli Proteins*/metabolism
Membrane Proteins/metabolism ; Cell Membrane/metabolism ; Protein Sorting Signals ; Maltose-Binding Proteins/genetics ; Maltose-Binding Proteins/metabolism ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/metabolism
Czasopismo naukowe
Tytuł:
Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study.
Autorzy:
Kodjikian L; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Université Lyon 1, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Abukhashabah A; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Ophthalmology Department, King Abdulaziz University, Rabigh, Saudi Arabia.
Fardeau C; Ophthalmology Department, Reference Center for Rare Diseases, La Pitié-Salpêtriètre Hospital, Paris-Sorbonne University, Paris, France.
Tadayoni R; Université de Paris, Service d'Ophtalmologie, AP-HP, Hôpital Lariboisière, Paris, France.; Service d'Ophtalmologie, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
Brézin A; Hôpital Cochin, Service d'Ophtalmologie, Université de Paris, Paris, France.
Dumas S; Centre Nordretine, Lille, France.
Weber M; Hôpital Universitaire Centre Nantes, Nantes, France.
Bernard L; Université Lyon 1, Lyon, France.; Pôle de Santé Publique, Service de Biostatistique et Bioinformatique, Hospices Civils de Lyon, Lyon, France.; CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbane, France.
Loria O; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Decullier E; Pôle de Santé Publique, Service Recherche et Epidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
Huot L; Université Lyon 1, Lyon, France.; Pôle de Santé Publique, Service Recherche et Epidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
Mathis T; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Université Lyon 1, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Pokaż więcej
Źródło:
Acta ophthalmologica [Acta Ophthalmol] 2023 Feb; Vol. 101 (1), pp. e43-e49. Date of Electronic Publication: 2022 Jul 13.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/administration & dosage
Angiogenesis Inhibitors*/adverse effects
Choroidal Neovascularization*/drug therapy
Receptors, Vascular Endothelial Growth Factor*/administration & dosage
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/adverse effects
Humans ; Intravitreal Injections ; Prospective Studies ; Treatment Outcome ; Visual Acuity
Czasopismo naukowe
Tytuł:
Development of hybrid biomicroparticles: cellulose exposing functionalized fusion proteins.
Autorzy:
Żebrowska J; Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, 80-308, Poland. .; BioVentures Institute Ltd, Poznan, 60-141, Poland. .
Mucha P; Department of Molecular Biochemistry, Faculty of Chemistry, University of Gdansk, Gdansk, 80-308, Poland.
Prusinowski M; Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, 80-308, Poland.
Krefft D; Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, 80-308, Poland.; BioVentures Institute Ltd, Poznan, 60-141, Poland.
Żylicz-Stachula A; Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, 80-308, Poland.; BioVentures Institute Ltd, Poznan, 60-141, Poland.
Deptuła M; Laboratory of Tissue Engineering and Regenerative Medicine, Division of Embryology, Faculty of Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland.
Skoniecka A; Laboratory of Tissue Engineering and Regenerative Medicine, Division of Embryology, Faculty of Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland.
Tymińska A; Laboratory of Tissue Engineering and Regenerative Medicine, Division of Embryology, Faculty of Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland.
Zawrzykraj M; Division of Clinical Anatomy, Faculty of Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland.
Zieliński J; Department of Oncologic Surgery, Faculty of Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland.
Pikuła M; Laboratory of Tissue Engineering and Regenerative Medicine, Division of Embryology, Faculty of Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland.
Skowron PM; Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, 80-308, Poland.; BioVentures Institute Ltd, Poznan, 60-141, Poland.
Pokaż więcej
Źródło:
Microbial cell factories [Microb Cell Fact] 2024 Mar 14; Vol. 23 (1), pp. 81. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Cellulose*/metabolism
Biotechnology*
Humans ; Recombinant Fusion Proteins/metabolism ; Recombinant Proteins/genetics ; Hydrolysis
Czasopismo naukowe
Tytuł:
Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.
Autorzy:
Mititelu A; Department of Hematology, Carol Davila University of Medicine and Pharmacy, Emergency University Hospital of Bucharest, 050098 Bucharest, Romania.
Onisâi MC; Department of Hematology, Carol Davila University of Medicine and Pharmacy, Emergency University Hospital of Bucharest, 050098 Bucharest, Romania.
Roșca A; Department of Physiology, Carol Davila University of Medicine and Pharmacy, 050471 Bucharest, Romania.
Vlădăreanu AM; Department of Hematology, Carol Davila University of Medicine and Pharmacy, Emergency University Hospital of Bucharest, 050098 Bucharest, Romania.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 10; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/etiology
Purpura, Thrombocytopenic, Idiopathic*/therapy
Thrombocytopenia*/drug therapy
Adult ; Infant, Newborn ; Humans ; Quality of Life ; Platelet Count ; Immunoglobulins, Intravenous/therapeutic use ; Thrombopoietin ; Recombinant Fusion Proteins/therapeutic use
Czasopismo naukowe
Tytuł:
Targeted Delivery of HSP70 to Tumor Cells via Supramolecular Complex Based on HER2-Specific DARPin9_29 and the Barnase:Barstar Pair.
Autorzy:
Alekseeva LG; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Ovsyanikova OV; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.; Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia.
Schulga AA; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Grechikhina MV; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Shustova OA; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Kovalenko EI; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Svirshchevskaya EV; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Deyev SM; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.; Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia.
Sapozhnikov AM; M.M. Shemyakin and Y.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.; Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia.
Pokaż więcej
Źródło:
Cells [Cells] 2024 Feb 09; Vol. 13 (4). Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*
Carcinoma*
Bacterial Proteins*
Ribonucleases*
Humans ; Recombinant Fusion Proteins/metabolism ; HSP70 Heat-Shock Proteins
Czasopismo naukowe
Tytuł:
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Autorzy:
Coleman N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Subbiah V; Early Phase Drug Development, Sarah Cannon Research Institute, Nashville, Tennessee, USA.
Ahnert JR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wright J; National Cancer Institute (NCI), Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland, USA.
Fessahaye SN; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ouyang F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Khalifa Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, Texas, USA.; Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6877.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Neoplasms*/drug therapy
Neoplasms*/etiology
Benzoxazoles*
Adenine/*analogs & derivatives
Humans ; Female ; Middle Aged ; Male ; Treatment Outcome ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration.
Autorzy:
Archambault SD; Division of Ophthalmology, Department of Surgery, Lahey Hospital & Medical Center, 1 Essex Center Drive, Peabody, MA, USA.; Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.
Nichols MM; Division of Ophthalmology, Department of Surgery, Lahey Hospital & Medical Center, 1 Essex Center Drive, Peabody, MA, USA.; Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.
McCullum JC; Division of Ophthalmology, Department of Surgery, Lahey Hospital & Medical Center, 1 Essex Center Drive, Peabody, MA, USA.; Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.
Zhang Y; Division of Ophthalmology, Department of Surgery, Lahey Hospital & Medical Center, 1 Essex Center Drive, Peabody, MA, USA.; Brandeis University, Waltham, MA, USA.
Steinberger EE; Division of Ophthalmology, Department of Surgery, Lahey Hospital & Medical Center, 1 Essex Center Drive, Peabody, MA, USA.; Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.
Ramsey DJ; Division of Ophthalmology, Department of Surgery, Lahey Hospital & Medical Center, 1 Essex Center Drive, Peabody, MA, USA.; Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.
Pokaż więcej
Źródło:
Indian journal of ophthalmology [Indian J Ophthalmol] 2024 Jan 01; Vol. 72 (Suppl 1), pp. S101-S105. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:
Journal Article
MeSH Terms:
Ranibizumab*
Macular Degeneration*
Humans ; Bevacizumab ; Angiogenesis Inhibitors ; Retrospective Studies ; Cross-Sectional Studies ; Treatment Outcome ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins/therapeutic use ; Intravitreal Injections ; Patient Compliance
Czasopismo naukowe
Tytuł:
Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.
Autorzy:
Zhu J; Beijing Key Lab of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Li X; College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Gao W; College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Jing J; Beijing Key Lab of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 15; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Annexin A5*/therapeutic use
Integrin alpha1beta1*/metabolism
Melanoma*/therapy
Recombinant Fusion Proteins*/therapeutic use
Skin Neoplasms*/therapy
Animals ; Humans ; Mice ; Melanoma, Experimental ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Tytuł:
Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
Autorzy:
Zhang H; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Yang X; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Zheng F; Neonatal Intensive Care Unit of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Wan S; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Xu Y; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Pokaż więcej
Źródło:
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde [Ophthalmologica] 2023; Vol. 246 (2), pp. 81-89. Date of Electronic Publication: 2023 Jan 27.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Ranibizumab*/therapeutic use
Retinopathy of Prematurity*/diagnosis
Retinopathy of Prematurity*/drug therapy
Recombinant Fusion Proteins*/therapeutic use
Humans ; Infant ; Infant, Newborn ; Intravitreal Injections ; Prospective Studies ; Vascular Endothelial Growth Factor A/blood ; Vascular Endothelial Growth Factor B/blood ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action.
Autorzy:
Miroshnichenko S; Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Pykhtina M; Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Kotliarova A; N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Chepurnov A; Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Beklemishev A; Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Dec 08; Vol. 28 (24). Date of Electronic Publication: 2023 Dec 08.
Typ publikacji:
Journal Article
MeSH Terms:
Interferon-alpha*/genetics
Interferon-alpha*/pharmacology
Apolipoproteins A*
Chlorocebus aethiops ; Humans ; Mice ; Animals ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/pharmacology ; Recombinant Fusion Proteins/chemistry ; Apolipoprotein A-I/genetics ; Vero Cells ; Recombinant Proteins/genetics ; Recombinant Proteins/pharmacology ; Interferon alpha-2
Czasopismo naukowe
Tytuł:
Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.
Autorzy:
Vugmeyster Y; EMD Serono, Billerica, Massachusetts, USA.
Locke G; EMD Serono, Billerica, Massachusetts, USA.
Helwig C; The Healthcare Business of Merck KGaA, Darmstadt, Germany.
Rolfe PA; EMD Serono, Billerica, Massachusetts, USA.
Dong JQ; EMD Serono, Billerica, Massachusetts, USA.
Venkatakrishnan K; EMD Serono, Billerica, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Dec; Vol. 15 (12), pp. 2838-2843. Date of Electronic Publication: 2022 Oct 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Recombinant Fusion Proteins*/pharmacology
Humans ; Drug Interactions ; Risk Assessment ; RNA, Messenger/genetics ; Transforming Growth Factor beta
Czasopismo naukowe
Tytuł:
Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals.
Autorzy:
Thébault S; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Lejal N; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Dogliani A; Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, UMR, Marseille, France.
Donchet A; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Urvoas A; Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette cedex, France.
Valerio-Lepiniec M; Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette cedex, France.
Lavie M; Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Baronti C; Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France.
Touret F; Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France.
Da Costa B; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Bourgon C; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Fraysse A; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Saint-Albin-Deliot A; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Morel J; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Klonjkowski B; UMR Virologie, INRAE-ENVA-ANSES, École Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, Paris, France.
de Lamballerie X; Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France.
Dubuisson J; Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Roussel A; Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, UMR, Marseille, France.
Minard P; Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette cedex, France.
Le Poder S; UMR Virologie, INRAE-ENVA-ANSES, École Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, Paris, France.
Meunier N; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Delmas B; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2022 Sep 06; Vol. 18 (9), pp. e1010799. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Angiotensin-Converting Enzyme 2*/chemistry
Angiotensin-Converting Enzyme 2*/metabolism
Recombinant Fusion Proteins*/pharmacology
Recombinant Fusion Proteins*/therapeutic use
Spike Glycoprotein, Coronavirus*/metabolism
COVID-19 Drug Treatment*
Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Humans ; Peptidyl-Dipeptidase A/metabolism ; Protein Binding ; Recombinant Proteins/pharmacology ; Recombinant Proteins/therapeutic use ; SARS-CoV-2/genetics
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.
Autorzy:
di Leandro L; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Colasante M; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Pitari G; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Ippoliti R; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Pokaż więcej
Źródło:
Toxins [Toxins (Basel)] 2023 Dec 13; Vol. 15 (12). Date of Electronic Publication: 2023 Dec 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Bacterial Toxins*/genetics
Bacterial Toxins*/therapeutic use
Immunotoxins*/genetics
Immunotoxins*/therapeutic use
Neoplasms*/drug therapy
Humans ; Animals ; Diphtheria Toxin/genetics ; Pseudomonas aeruginosa Exotoxin A ; Recombinant Fusion Proteins/therapeutic use ; Exotoxins/genetics ; Mammals
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies